The purpose of this study is to find alternative treatments for patient's suffering from depression after having a stroke.This study aims to show that accelerated rTMS is a safe, effective,and convenient treatment for patient's suffering from post-stroke depression in the acute to subacute phase. This will be an open label trial and thus all participants will receive the active rTMS intervention.
The primary objectives of this project are as follows: 1. To assess the efficacy TMS in PSD. We hypothesize that there will be a decrease in the HAMD score in patients receiving TMS 2. To assess the feasibility of an accelerated protocol using rTMS in patients with acute to subacute stroke and co-existing PSD. We hypothesize that the accelerated protocol will promote compliance in our patient population and that the administration of this intervention is feasible. 3. To assess the safety of rTMS in patients with acute to subacute stroke. We hypothesize that the side effects of TMS will be minimal and the therapy will be well-tolerated and safe in individuals with recent strokes and co-existing PSD.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
NeuroStar TMS Therapy
West Virginia University
Morgantown, West Virginia, United States
Number of Participants With Adverse Events
Count of Adverse Events Reported during follow up
Time frame: After Day 1 of rTMS treatment
Number of Participants With Adverse Events
Count of Adverse Events Reported during follow up
Time frame: After Day 2 of rTMS treatment
Number of Participants With Adverse Events
Count of Adverse Events Reported during follow up
Time frame: After Day 3 of rTMS treatment
Number of Participants With Adverse Events
Count of Adverse Events Reported during follow up
Time frame: After Day 4 of rTMS treatment
Number of Participants With Adverse Events
Count of Adverse Events Reported during follow up
Time frame: 3 months following neurostimulation
Number of Participants With Adverse Events
Count of Adverse Events Reported during follow up
Time frame: 6 months following neurostimulation
Number of Participants With Adverse Events
Count of Adverse Events Reported during follow up
Time frame: 12 months following neurostimulation
Depressive Symptoms as Rated by the Hamilton Depression Rating Scale
Depressive symptoms as rated by the Hamilton Depression Rating Scale. Measure of severity of depression -total score of Hamilton Depression Scale ranges from 0 (no depression) to 60 (worst depression possible)
Time frame: Depressive symptoms will be quantified before the rTMS stimulation protocol
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Depressive Symptoms as Rated by the Hamilton Depression Rating Scale
Depressive symptoms as rated by the Hamilton Depression Rating Scale. Measure of severity of depression -total score of Hamilton Depression Scale ranges from 0 (no depression) to 60 (worst depression possible)
Time frame: Depressive symptoms will be quantified immediately after the 4 days of rTMS stimulation.
Depressive Symptoms as Rated by the Hamilton Depression Rating Scale
Depressive symptoms as rated by the Hamilton Depression Rating Scale. Measure of severity of depression -total score of Hamilton Depression Scale ranges from 0 (no depression) to 60 (worst depression possible)
Time frame: Depressive symptoms will be quantified 3 months after completion of the rTMS stimulation protocol.
Depressive Symptoms as Rated by the Hamilton Depression Rating Scale
Depressive symptoms as rated by the Hamilton Depression Rating Scale. Measure of severity of depression -total score of Hamilton Depression Scale ranges from 0 (no depression) to 60 (worst depression possible)
Time frame: Depressive symptoms will be quantified 6 months after completion of the rTMS stimulation protocol.
Depressive Symptoms as Rated by the Hamilton Depression Rating Scale
Depressive symptoms as rated by the Hamilton Depression Rating Scale. Measure of severity of depression -total score of Hamilton Depression Scale ranges from 0 (no depression) to 60 (worst depression possible)
Time frame: Depressive symptoms will be quantified 12 months after completion of the rTMS stimulation protocol.